GlassScriptPhysician profile
Scott C Blair
NPI 1922004399
$4,347.89
in general payments reported to CMS, 2019-2025
18 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $2,819 · 2021: $42.43 · 2022: $882 · 2023: $213 · 2024: $33.33 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405 · Education: $96.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.27 |
| Education | $96.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $3,636.53 | 2020-2022 | |
| Abbott Laboratories | $159.09 | 2025 | Proclaim |
| Mckesson Specialty Care Distribution, LLC | $117.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.26 | 2021-2025 | Enhertu |
| Genentech USA, INC. | $53.45 | 2025 | |
| Astellas Pharma US INC | $40.15 | 2023 | |
| Taiho Oncology, INC. | $39.39 | 2023 | |
| Janssen Biotech, INC. | $38.49 | 2023-2024 | Tecvayli, Talvey, Carvykti |
| Pfizer INC. | $30.36 | 2023 | |
| Novartis Pharmaceuticals Corporation | $28.14 | 2023-2024 | |
| Amgen INC. | $27.05 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Janssen Scientific Affairs, LLC | $24.61 | 2023 | Xarelto |
| Genzyme Corporation | $19.40 | 2022 | |
| Merck Sharp & Dohme LLC | $17.75 | 2023 | Lynparza, Keytruda |
| Seagen INC. | $15.52 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.52 | 2023 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.